Correlation between pre-treatment quasispecies complexity and treatment outcome in chronic HCV genotype 3a

Virology Journal

Volumn 5, Issue , 2008, Pages

  Moreau, Isabelle ^a   Levis, John ^a   Crosbie, Orla ^a   Kenny Walsh, Elizabeth ^a   Fanning, Liam J ^a  

^a University College Cork and INFANT Centre   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; AMINO ACID; RIBAVIRIN; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; PEGINTERFERON ALFA-2A; PEGINTERFERON ALPHA2A;

ADULT; ARTICLE; BLOOD SAMPLING; CALCULATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENTROPY; EVOLUTION; FEMALE; GENE SEQUENCE; GENETIC DISTANCE; GENETIC HETEROGENEITY; GENETIC PARAMETERS; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HOMEOSTASIS; HUMAN; MALE; NUCLEOTIDE SEQUENCE; PREDICTION; RETROSPECTIVE STUDY; TREATMENT FAILURE; TREATMENT OUTCOME; VIROLOGY; CLASSIFICATION; DNA SEQUENCE; DRUG COMBINATION; DRUG EFFECT; GENETIC VARIABILITY; GENETICS; MIDDLE AGED; MOLECULAR EVOLUTION; MOLECULAR GENETICS; PHYLOGENY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRUS LOAD; VIRUS REPLICATION;

HEPATITIS C VIRUS;

ADULT; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; EVOLUTION, MOLECULAR; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; PHYLOGENY; POLYETHYLENE GLYCOLS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RIBAVIRIN; SEQUENCE ANALYSIS, DNA; TREATMENT FAILURE; TREATMENT OUTCOME; VARIATION (GENETICS); VIRAL LOAD; VIRUS REPLICATION;

EID: 48249089292     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-5-78     Document Type: Article

References (65)

1. NIH Consensus Statement on Management of Hepatitis C: 2002. NIH, NIH Consens State Sci Statements 2002 19 1 46
2. WHO, 2006 http://www.who.int/csr/disease/hepatitis/whocdscsrlyo2003/en/ index3.html
3. Hepatitis C: an update. D Moradpour A Cerny MH Heim HE Blum, Swiss Med Wkly 2001 131 291 298 11584690
4. Sequence variability in the 5' non-coding region of hepatitis C virus: identification of a new virus type and restrictions on sequence diversity. P Simmonds F McOmish PL Yap SW Chan CK Lin G Dusheiko AA Saeed EC Holmes, J Gen Virol 1993 74 Pt 4 661 668 10.1099/0022-1317-74-4-661 8385694
5. Variability of hepatitis C virus genome. P Simmonds, Curr Stud Hematol Blood Transfus 1994 12 35 7956326
6. The origin of hepatitis C virus genotypes. DB Smith S Pathirana F Davidson E Lawlor J Power PL Yap P Simmonds, J Gen Virol 1997 78 Pt 2 321 328 9018053
7. Clinical relevance of hepatitis C virus genotypes. P Simmonds, Gut 1997 40 291 293 9135513
8. The origin and evolution of hepatitis viruses in humans. P Simmonds, J Gen Virol 2001 82 693 712 11257174
9. Genetic diversity and evolution of hepatitis C virus-15 years on. P Simmonds, J Gen Virol 2004 85 3173 3188 10.1099/vir.0.80401-0 15483230
10. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. P Simmonds J Bukh C Combet G Deleage N Enomoto S Feinstone P Halfon G Inchauspe C Kuiken G Maertens M Mizokami DG Murphy H Okamoto JM Pawlotsky F Penin E Sablon IT Shin LJ Stuyver HJ Thiel S Viazov AJ Weiner A Widell, Hepatology 2005 42 962 973 10.1002/hep.20819 16149085
11. Epidemiology of hepatitis C: geographic differences and temporal trends. A Wasley MJ Alter, Semin Liver Dis 2000 20 1 16 10.1055/s-2000-9506 10895428
12. Hepatitis C virus: virology, diagnosis and management of antiviral therapy. S Chevaliez JM Pawlotsky, World J Gastroenterol 2007 13 2461 2466 17552030
13. Natural history of chronic hepatitis C. LB Seeff, Hepatology 2002 36 S35 46 10.1002/hep.1840360706 12407575
14. The origin of quasispecies: cause or consequence of chronic hepatitis C viral infection? DG Bowen CM Walker, J Hepatol 2005 42 408 417 10.1016/j.jhep.2004.12.013 15710225
15. Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution. M Martell JI Esteban J Quer J Genesca A Weiner R Esteban J Guardia J Gomez, J Virol 1992 66 3225 3229 1313927
16. Basic concepts in RNA virus evolution. E Domingo C Escarmis N Sevilla A Moya SF Elena J Quer IS Novella JJ Holland, Faseb J 1996 10 859 864 8666162
17. Population dynamics of RNA viruses: the essential contribution of mutant spectra. E Domingo C Gonzalez-Lopez N Pariente A Airaksinen C Escarmis, Arch Virol Suppl 2005 59 71 16355868
18. A hyperimmune serum against a synthetic peptide corresponding to the hypervariable region 1 of hepatitis C virus can prevent viral infection in cell cultures. YK Shimizu H Igarashi T Kiyohara T Cabezon P Farci RH Purcell H Yoshikura, Virology 1996 223 409 412 10.1006/viro.1996.0497 8806581
19. Clinical significance of hepatitis C virus genotypes and quasispecies. P Farci RH Purcell, Semin Liver Dis 2000 20 103 126 10895435
20. The hepatitis C virus: overview. R Purcell, Hepatology 1997 26 11S 14S 10.1002/hep.510260702 9305657
21. Cellular immune selection with hepatitis C virus persistence in humans. AL Cox T Mosbruger Q Mao Z Liu XH Wang HC Yang J Sidney A Sette D Pardoll DL Thomas SC Ray, J Exp Med 2005 201 1741 1752 15939790 10.1084/jem.20050121
22. Virus-specific T-cell responses associated with hepatitis C virus (HCV) persistence in the liver after apparent recovery from HCV infection. JA Quiroga S Llorente I Castillo E Rodriguez-Inigo JM Lopez-Alcorocho M Pardo V Carreno, J Med Virol 2006 78 1190 1197 10.1002/jmv.20680 16847959
23. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). T Poynard P Marcellin SS Lee C Niederau GS Minuk G Ideo V Bain J Heathcote S Zeuzem C Trepo J Albrecht, Lancet 1998 352 1426 1432 10.1016/S0140-6736(98)07124-4 9807989
24. Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group. O Reichard G Norkrans A Fryden JH Braconier A Sonnerborg O Weiland, Lancet 1998 351 83 87 10.1016/S0140-6736(97)06088-1 9439491
25. Hepatitis C therapy in treatment-naive patients. J McHutchison, Am J Med 1999 107 56S 61S 10.1016/S0002-9343(99)00384-8 10653459
26. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. GL Davis R Esteban-Mur V Rustgi J Hoefs SC Gordon C Trepo ML Shiffman S Zeuzem A Craxi MH Ling J Albrecht, N Engl J Med 1998 339 1493 1499 10.1056/NEJM199811193392102 9819447
27. Viral, host and interferon-related factors modulating the effect of interferon therapy for hepatitis C virus infection. KQ Hu JM Vierling AG Redeker, J Viral Hepat 2001 8 1 18 10.1046/j.1365-2893.2001.00253.x 11155147
28. Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome. P Farci R Strazzera HJ Alter S Farci D Degioannis A Coiana G Peddis F Usai G Serra L Chessa G Diaz A Balestrieri RH Purcell, Proc Natl Acad Sci USA 2002 99 3081 3086 11880647 10.1073/pnas. 052712599
29. Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease. R Thimme J Bukh HC Spangenberg S Wieland J Pemberton C Steiger S Govindarajan RH Purcell FV Chisari, Proc Natl Acad Sci USA 2002 99 15661 15668 12441397 10.1073/pnas.202608299
30. Factors predictive of response to interferon-alpha therapy in hepatitis C virus type 1b infection. BI Yeh KH Han HW Lee JH Sohn WS Ryu DJ Yoon J Yoon HW Kim ID Kong SJ Chang JW Choi, J Med Virol 2002 66 481 487 10.1002/jmv.2169 11857525
31. Genetic diversity of the hepatitis C virus: impact and issues in the antiviral therapy. H Le Guillou-Guillemette S Vallet C Gaudy-Graffin C Payan A Pivert A Goudeau F Lunel-Fabiani, World J Gastroenterol 2007 13 2416 2426 17552024
32. Therapy of chronic hepatitis C. D Moradpour HE Blum, Schweiz Rundsch Med Prax 2006 95 1451 1457
33. Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants: potential role in chronic HCV infections. AJ Weiner HM Geysen C Christopherson JE Hall TJ Mason G Saracco F Bonino K Crawford CD Marion KA Crawford M Brunetto PJ Barr T Miyamura J Mchutchinson M Houghton, Proc Natl Acad Sci USA 1992 89 3468 3472 1314389 10.1073/pnas.89.8.3468
34. Variability or conservation of hepatitis C virus hypervariable region 1? Implications for immune responses. MU Mondelli A Cerino A Meola A Nicosia, J Biosci 2003 28 305 310 12734408
35. Sequence variation in the hypervariable region 1 of hepatitis C virus and posttransplantation recurrent hepatitis. E Silini L Belli S Brambilla L Foti C Gritti A Lisa AB Alberti M Vinci L De Carlis G Rondinara G Pinzello, Liver Transpl 2003 9 1040 1047 10.1053/jlts.2003.50180 14526398
36. The hepatitis C virus persistence: how to evade the immune system? N Pavio MM Lai, J Biosci 2003 28 287 304 12734407
37. Quasispecies heterogeneity within the E1/E2 region as a pretreatment variable during pegylated interferon therapy of chronic hepatitis C virus infection. TJ Chambers X Fan DA Droll E Hembrador T Slater MW Nickells LB Dustin AM Dibisceglie, J Virol 2005 79 3071 3083 15709027 10.1128/JVI.79.5.3071-3083. 2005
38. Genetic heterogeneity of hypervariable region 1 of the hepatitis C virus (HCV) genome and sensitivity of HCV to alpha interferon therapy. K Sandres M Dubois C Pasquier JL Payen L Alric M Duffaut JP Vinel JP Pascal J Puel J Izopet, J Virol 2000 74 661 668 10623727 10.1128/JVI.74.2.661-668.2000
39. Quasispecies as predictive response factors for antiviral treatment in patients with chronic hepatitis C. J Salmeron PM De Rueda A Ruiz-Extremera J Casado C Huertas C Bernal Mdel L Rodriguez A Palacios, Dig Dis Sci 2006 51 960 967 10.1007/s10620-006-9347-2 16758308
40. Evolution of the hepatitis C virus second envelope protein hypervariable region in chronically infected patients receiving alpha interferon therapy. JM Pawlotsky G Germanidis PO Frainais M Bouvier A Soulier M Pellerin D Dhumeaux, J Virol 1999 73 6490 6499 10400744
41. Prospective study on early virologic response to treatment with interferon alpha-2b plus ribavirin in patients with chronic hepatitis C genotype 1b. M Nagaki M Imose T Naiki K Kimura H Hayashi M Shimizu H Ohnishi E Tomita J Sugihara K Amano T Sakai T Kojima N Katsumura Y Kondo M Fujimoto H Moriwaki, Hepatol Res 2005 33 285 291 10.1016/j.hepres.2005.08.010 16298546
42. Complexity of the HVR-1 quasispecies and disease activity in patients with hepatitis C. N Kumagai F Kaneko S Tsunematsu K Tsuchimoto S Tada H Saito T Hibi, Eur J Clin Invest 2007 37 566 572 10.1111/j.1365-2362.2007.01825.x 17576208
43. HVR-1 quasispecies modifications occur early and are correlated to initial but not sustained response in HCV-infected patients treated with pegylated- or standard-interferon and ribavirin. I Abbate O Lo Iacono R Di Stefano G Cappiello E Girardi R Longo D Ferraro G Antonucci V Di Marco M Solmone A Craxi G Ippolito MR Capobianchi, J Hepatol 2004 40 831 836 10.1016/j.jhep.2004.01.019 15094232
44. Replicative homeostasis: a mechanism of viral persistence. R Sallie, Med Hypotheses 2004 63 515 523 10.1016/j.mehy.2004.02.050 15288380
45. Replicative homeostasis: a fundamental mechanism mediating selective viral replication and escape mutation. R Sallie, Virol J 2005 2 10 15707489 10.1186/1743-422X-2-10
46. Replicative homeostasis II: influence of polymerase fidelity on RNA virus quasispecies biology: implications for immune recognition, viral autoimmunity and other "virus receptor" diseases. R Sallie, Virol J 2005 2 70 16115320 10.1186/1743-422X-2-70
47. Replicative homeostasis III: implications for antiviral therapy and mechanisms of response and non-response. R Sallie, Virol J 2007 4 29 17355620 10.1186/1743-422X-4-29
48. A valine to phenylalanine mutation in the precore region of hepatitis B virus causes intracellular retention and impaired secretion of HBe-antigen. CY Chen C Crowther MC Kew A Kramvis, Hepatol Res 2008 38 580 92 18201182 10.1111/j.1872-034X.2007.00315.x
49. Exploring differences in response to treatment with peginterferon alpha 2a (40 kD) and ribavirin in chronic hepatitis C between genotypes 2 and 3. J Powis KM Peltekian SS Lee M Sherman VG Bain C Cooper M Krajden M Deschenes RF Balshaw EJ Heathcote EM Yoshida, J Viral Hepat 2008 15 52 57 18088245
50. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. A Mangia R Santoro N Minerva GL Ricci V Carretta M Persico F Vinelli G Scotto D Bacca M Annese M Romano F Zechini F Sogari F Spirito A Andriulli, N Engl J Med 2005 352 2609 2617 10.1056/NEJMoa042608 15972867
51. Inferred hepatitis C virus quasispecies diversity is influenced by choice of DNA polymerase in reverse transcriptase-polymerase chain reactions. B Mullan E Kenny-Walsh JK Collins F Shanahan LJ Fanning, Anal Biochem 2001 289 137 146 10.1006/abio.2000.4946 11161307
52. Mother-to-child transmission of a hepatitis C virus variant with an insertional mutation in its hypervariable region. H Aizaki A Saito I Kusakawa Y Ashiwara S Nagamori G Toda T Suzuki K Ishii Y Matsuura T Miyamura, J Hepatol 1996 25 608 613 10.1016/S0168-8278(96)80227-3 8938534
53. Marked sequence diversity in the putative envelope proteins of hepatitis C viruses. N Kato Y Ootsuyama T Tanaka M Nakagawa T Nakazawa K Muraiso S Ohkoshi M Hijikata K Shimotohno, Virus Res 1992 22 107 123 10.1016/0168-1702(92)90038-B 1314471
54. Genomic characterization and mutation rate of hepatitis C virus isolated from a patient who contracted hepatitis during an epidemic of non-A, non-B hepatitis in Japan. K Abe G Inchauspe K Fujisawa, J Gen Virol 1992 73 Pt 10 2725 2729 10.1099/0022-1317-73-10-2725 1383400
55. Sequence variability in the env-coding region of hepatitis C virus isolated from patients infected during a single source outbreak. M Hohne E Schreier M Roggendorf, Arch Virol 1994 137 25 34 10.1007/BF01311170 7979995
56. A 385 insertion in the hypervariable region 1 of hepatitis C virus E2 envelope protein is found in some patients with mixed cryoglobulinemia type 2. M Gerotto F Dal Pero S Loffreda FB Bianchi A Alberti M Lenzi, Blood 2001 98 2657 2663 10.1182/blood.V98.9.2657 11675335
57. Contribution of insertions and deletions to the variability of hepatitis C virus populations. M Torres-Puente JM Cuevas N Jimenez-Hernandez MA Bracho I Garcia-Robles F Carnicer J del Olmo E Ortega A Moya F Gonzalez-Candelas, J Gen Virol 2007 88 2198 2203 10.1099/vir.0.82855-0 17622623
58. Diagnosis and treatment of chronic hepatitis C infection. K Patel AJ Muir JG McHutchison, Bmj 2006 332 1013 1017 16644828 10.1136/bmj.332.7548.1013
59. Occurrence of identical hypervariable region 1 sequences of hepatitis C virus in transfusion recipients and their respective blood donors: divergence over time. HJ Lin LB Seeff L Barbosa FB Hollinger, Hepatology 2001 34 424 429 10.1053/jhep.2001.26635 11481629
60. Avoiding false positives with PCR. S Kwok R Higuchi, Nature 1989 339 237 238 10.1038/339237a0 2716852
61. Protecting HIV databases. BT Korber G Learn JI Mullins BH Hahn S Wolinsky, Nature 1995 378 242 244 10.1038/378242a0 7477340
62. Serendipitous identification of natural intergenotypic recombinants of hepatitis C in Ireland. I Moreau S Hegarty J Levis P Sheehy O Crosbie E Kenny-Walsh LJ Fanning, Virol J 2006 3 95 17107614 10.1186/1743-422X-3-95
63. MEGA2: molecular evolutionary genetics analysis software. S Kumar K Tamura IB Jakobsen M Nei, Bioinformatics 2001 17 1244 1245 10.1093/ bioinformatics/17.12.1244 11751241
64. MV Volkenstein, Physical approaches to biological evolution Berlin, Germany: Springer-Verlag 1994
65. Phylogeny Inference Package. J Felsenstein, University of Washington, Seattle, USA 1995